Provided by Tiger Trade Technology Pte. Ltd.

Alzamend Neuro, Inc

1.65
+0.02001.23%
Post-market: 1.60-0.0500-3.03%17:33 EST
Volume:97.95K
Turnover:160.04K
Market Cap:6.27M
PE:-0.29
High:1.71
Open:1.67
Low:1.58
Close:1.63
52wk High:10.35
52wk Low:1.58
Shares:3.80M
Float Shares:3.78M
Volume Ratio:1.10
T/O Rate:2.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.7065
EPS(LYR):-11.3245
ROE:-144.76%
ROA:-72.71%
PB:1.43
PE(LYR):-0.15

Loading ...

Alzamend Neuro Inc. Announces Date for 2026 Annual Meeting of Stockholders

Reuters
·
Feb 10

Director Milton C. Ault III Reports Sale of Alzamend Neuro Inc. Common Shares

Reuters
·
Dec 31, 2025

Director William B. Horne Reports Disposal of Alzamend Neuro Inc. Common Shares

Reuters
·
Dec 24, 2025

Alzamend Neuro Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 22, 2025

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Reuters
·
Dec 22, 2025

Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate

Benzinga
·
Dec 10, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet

Reuters
·
Nov 20, 2025

BRIEF-Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study Conducted At Massachusetts General Hospital

Reuters
·
Nov 19, 2025

BUZZ-Alzamend rises after completing mid-stage brain lithium study

Reuters
·
Nov 19, 2025

Alzamend Neuro Announces Completion of Clinical Portion of Phase Ii Clinical Trial of Al001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

THOMSON REUTERS
·
Nov 19, 2025

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants

Benzinga
·
Nov 19, 2025

Alzamend Neuro Mourns Loss of Director Andrew Woo

TIPRANKS
·
Nov 19, 2025

Alzamend Neuro Director Lynne Fahey McGrath Reports Sale of Common Shares

Reuters
·
Oct 25, 2025

Alzamend Neuro Inc Issues 361743 Shares of Common Stock Upon Conversion of Series B Preferred

Reuters
·
Oct 10, 2025

Director’s Major Stock Sale Shakes Up Alzamend Neuro!

TIPRANKS
·
Oct 01, 2025

Alzamend Neuro Inc. Director and 10% Owner Milton C. Ault III Reports Disposal of Common Shares

Reuters
·
Oct 01, 2025

Alzamend Neuro Inc. Issues 300,000 Common Shares Upon Conversion of Series B Preferred Stock

Reuters
·
Sep 26, 2025

Alzamend Neuro Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Sep 25, 2025

U.S. RESEARCH ROUNDUP- Apogee Therapeutics, Intel, Northern Trust

Reuters
·
Sep 25, 2025

Alzamend Neuro Inc : Ascendiant Capital Markets Cuts Target Price to $42 From $45

THOMSON REUTERS
·
Sep 25, 2025